Genscript Biotech (01548) saw its stock price climb more than 7% during intraday trading, reflecting strong investor confidence. At the time of writing, shares were trading 5.34% higher at HK$41.44, with trading turnover reaching HK$977 million.

The rally follows the company's recent announcement of a partnership with Lilly's AI-driven drug discovery platform, Lilly TuneLab. Under this collaboration, Genscript Biotech will offer wet lab services to TuneLab participating companies, enabling them to rapidly generate experimental data. This initiative aims to transform AI predictions into validated biological insights, accelerating the evaluation of drug candidates.

JPMorgan has released a research note in response to Eli Lilly's (LLY.US) TuneLab collaboration announcement, which includes a partnership with Genscript Biotech (01548). The investment bank has maintained its "Overweight" rating on the stock, along with a target price of HK$41. JPMorgan highlighted that Genscript will provide wet lab services to TuneLab member companies, covering gene synthesis, protein expression, purification, and testing under standardized protocols. These services are designed to help convert AI-generated drug candidates into experimental results, which the bank believes will strengthen Genscript's leadership position in the AI-driven drug discovery (AIDD) ecosystem.